Patent foramen ovale (PFO) and atrial septal defect (ASD) closure
Furthermore, it allows physicians to choose the optimal treatment, which is defect closure. This can be done either by heart surgery (suturing of a patch for very large and particular defects) or by the implantation of an umbrella-type device through a catheter inserted into a vein in the groin.
This percutaneous technique has been around for many years with excellent results both from a clinical (symptoms) and objective (regression of the dilatation of the right heart chambers) point of view. It is therefore the treatment of choice for any ASD if technically feasible.Contrary to the ASD, the PFO is not a permanent defect. This remnant from the fetal heart rather acts like a door capable of opening from the right to the left side. Normally, this defect should close after birth but autopsy studies have shown that up to 25% of the general population has a PFO. This condition generally causes no harm during the course of life but over the last decades it has been associated with several diseases so much so that manner that percutaneous closure (technically basically almost identical to ASD closure) has been advocated.
A first condition is stroke of unknown cause in young (<55 years) patients. The prevalence of PFO is significantly higher in these patients compared to stroke patients with known cause. Even more, patients at risk for recurrence of stroke have been identified based on clinical and anatomic characteristics. The proposed mechanism for stroke in these patients is the embolisation of a blood clot from the veins into the heart and passing through the PFO into the arterial circulation up to the brain. These clots may for example be formed during a period of prolonged rest and the PFO door is mostly opened during the so-called Valsalva maneuver. This maneuver (to forcibly exhale while keeping the mouth and nose closed) occurs often during daily life (lifting objects, moving the bowels). Randomized controlled trials (RCT) comparing device closure versus "best" medical therapy (antiplatelet or anticoagulation therapy) have been ongoing for years and are still not terminated. Therefore, most cardiology centers that practice PFO closure in Europe adapt a pragmatic approach and close PFO's estimated at high risk for recurrence. In the U.S., the HDE rule is applied.
Secondly, PFO has been been associated with migraine and aura. It has been shown that the prevalence of large PFO's in migraine with aura patients is up to 6 time higher than in the general population. A proposed mechanism in this condition is the passage of chemical substances from the right circulation through the PFO to the brain to trigger constriction of the brain vessels. A RCT (the MIST trial) has been concluded, presented at international meetings and will be published in due course. This study, comparing device closure to a sham procedure, did not demonstrate complete elimination of migraines but revealed less frequent and shorter migraine periods. Several other RCT are currently ongoing with final results to be expected within 2 years.
Third, it has been shown that divers with a PFO have a 5 fold risk of unexplained and severe decompression illness. Scuba divers may, depending on duration and depth of diving, develop bubbles in the veins. These bubbles are mostly small and are therefore trapped in the lung circulation and filtered out. In case of a large PFO, these bubbles may cross the PFO to the brain circulation and thereby cause decompression illness. Although it is generally accepted that large PFO's are a contra-indication for diving, there are no real European recommendations on screening or treatment of "PFO - divers".
The presence of a PFO has been associated with other more rare clinical entities and research is ongoing in emerging conditions such as the "sleep-apnea syndrome".
In conclusion, if the diagnosis of an ASD has been established, percutaneous closure by an umbrella-type device is preferred if technically feasible. The presence of a PFO is no longer considered as an "innocent bystander" in the general population. It has been associated with stroke of unknown cause in young patients, with migraine with aura and decompression illness in divers. Further clinical research will establish candidates for percutaneous closure. In the meantime, closure is proposed under certain circumstances.
Notes to the editors:
This study was presented at the ESC Congress 2007 in Vienna.
The European Society of Cardiology (ESC)
The ESC represents nearly 53,000 cardiology professionals across Europe and the Mediterranean. Its mission is to reduce the burden of cardiovascular disease in Europe.
The ESC achieves this through a variety of scientific and educational activities including the coordination of: clinical practice guidelines, education courses and initiatives, pan-European surveys on specific disease areas and the ESC Annual Congress, the largest medical meeting in Europe. The ESC also works closely with the European Commission and WHO to improve health policy in the EU.
The ESC comprises 3 Councils, 5 Associations, 19 Working Groups, 50 National Cardiac Societies and an ESC Fellowship Community (Fellow, FESC; Nurse Fellow, NFESC). For more information on ESC Initiatives, Congresses and Constituent Bodies see www.escardio.org.
European Society of Cardiology, The European Heart House 2035 Route des Colles, B.P. 179 - Les Templiers, Sophia Antipolis F-06903 France
About the Author(s)
Professor Eric Eeckhout
Chuv Lausanne Switzerland
Be the first to comment on this!
Personal Subscriber? Sign In
Note: Please enter a display name. Your email address will not be publically displayed